Navigation Links
Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
Date:5/9/2008

Growth of promoted products and reduced operating costs drive solid

earnings growth.

ST. DAVID'S, Bermuda, May 9 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) today announced its results for the quarter ended March 31, 2008. Revenue in the quarter ended March 31, 2008 totaled $229.5 million, an increase of 5.1%, over the prior year quarter. The primary drivers of the increase in revenue were the net sales of our promoted products LOESTRIN 24 FE, DORYX, TACLONEX and FEMCON FE, which together contributed $34.4 million of revenue growth for the quarter ended March 31, 2008 compared to the prior year quarter. The growth delivered by these products was offset primarily by a significant decline in ESTROSTEP FE revenue due to generic competition.

The Company reported net income of $33.7 million ($0.13 per diluted share) in the quarter ended March 31, 2008, compared with a net loss of $4.5 million ($0.02 per diluted share) in the prior year quarter. Cash net income ("CNI") in the quarter ended March 31, 2008 was $82.9 million, an increase of $31.9 million, compared to $51.0 million in the prior year quarter.

References in this release to "cash net income" or "CNI" mean the Company's net income/(loss) adjusted for the after-tax effects of two non-cash items: amortization of intangible assets and amortization (or write-off) of deferred loan costs related to the Company's debt. Reconciliations from the Company's reported results in accordance with US GAAP to cash net income, adjusted cash net income and adjusted EBITDA for all periods are presented in the tables at the end of this press release.

Revenue

Revenue in the quarter ended March 31, 2008 was $229.5 million
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
2. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
7. Warner Chilcott Reports the Death of Its Director James Andress
8. Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers Movie to Be Filmed About Him
9. Warner Chilcott Announces Earnings Release Date and Conference Call for First Quarter 2008 Financial Results
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. QMed, Inc. Reports July Medicare SNP Enrollments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... May 23, 2013 Pusan National University ... private biotherapeutics and contract research company focused on ... cancer, announced today a publication reporting the induction ... the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; ... published in the May 15 th , 2013 ...
(Date:5/23/2013)... Louis, Missouri (PRWEB) May 23, 2013 ... and manufacture of complete thermal systems, recently introduced ... than 90 years of experience in designing and ... complete selection of products to serve diverse customer ... options is featured at the beginning of the ...
(Date:5/22/2013)... iLuv Creative Technology, the premier provider ... mobile lifestyle, announces they are now shipping MultiCharger-X, an ... iPad devices efficiently. Winner of the 2013 internationally recognized ... award, MultiCharger-X is revolutionizing the way businesses, schools, and ... , MultiCharger-X (iAD910) combines the best ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Watlow Introduces Its New Industrial Heater Catalog 2iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3
... NEW ODOR ELIMINATOR, WHAT ODOR?® Signature pitchman, Billy Mays ENDORSES AND ... ... For The Earth Corp is pleased to announce the launch of a ... marketer Billy Mays., , , , ,Nelson Grist, Founder and CEO of ...
... DIEGO, March 2 BioMed Realty Trust, Inc. (NYSE: ... its executive management will present at the Citi 2009 ... 9:05 a.m. Eastern Standard Time on Wednesday, March 4, ... calling 719.785.5595 and providing the passcode 348395. About BioMed ...
... to Revolutionize Food Processing, Industry,VANCOUVER, ... ("EnWave" or "the Company") today announced that it ... nutraREV(TM) food dehydration equipment to CAL-SAN Enterprises, Ltd. ... blueberry producers. With this sale, EnWave has proven ...
Cached Biology Technology:Billy Mays Endorses New Odor Eliminating Product, What Odor? 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4
(Date:5/23/2013)... for the overall health, development, and academic success ... in ensuring that all students have opportunities to ... of vigorous or moderate-intensity physical activity, says a ... Recent estimates suggest that only about half of ... better health and development. The report recommends ...
(Date:5/23/2013)... succeeded in treating cerebral palsy with autologous cord blood. ... 2.5 year old boy had been in a persistent ... two months after treatment with the cord blood containing ... months, the child learned to speak simple sentences and ... Korean study, dispel the long-held doubts about the effectiveness ...
(Date:5/23/2013)... team reveal the interplay of brain chemicals which help ... Trust and BBSRC. , By changing the way ... abilities. While these changes can affect the strength of ... of that response. , Lead author Alex ... with others, you can make yourself better heard by ...
Breaking Biology News(10 mins):Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... role in the brain's ability to monitor body fat content ... diabetes, according to a new report in the August issue ... particular variants of the protein SH2-B might underlie obesity in ... in cells throughout the body, keeps the brain sensitive to ...
... Institute (BGI) of the Chinese Academy of Sciences (CAS) ... (DCPBP) jointly announce the public release of pig genomic ... of the genomes of five different domestic pig breeds ... the first large scale pig genome sequencing effort, the ...
... methods helped public health officials control and limit the ... virus in 2003 related to the consumption of green ... October 15 issue of The Journal of Infectious Diseases, ... Joseph J. Amon, PhD, MSPH, and colleagues at the ...
Cached Biology News:Weight control protein may yield antiobesity drugs 2Weight control protein may yield antiobesity drugs 3‘Blue Brain?project explores thought at molecular level 2Large-scale Computer Simulations Reveal New Insights Into Antibiotic Resistance 2
Monoclonal antibodies conjugated with rhodamine...
... lightweight, the Moticam 2300 camera (MC2300) attaches ... eyetube, or trinocular port. Included in the ... Images 2.0ML software offers quick and accurate ... maximize resolution for examination or documentation purposes. ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... BSA-Free Stabilizer is a bovine protein-free ... It is an aqueous solution that ... MOPS buffer (3-(N-Morpholino) propanesulfonic acid), pH ... combination of 0.02% methylisothiazolone and 0.02% ...
Biology Products: